Ravoxertinib (GDC-0994) is primarily investigated for its potential in cancer treatment, particularly targeting tumors with specific genetic mutations. It functions as an inhibitor of the ERK signaling pathway, which is often dysregulated in various cancers, including melanoma, colorectal cancer, and pancreatic cancer. By blocking this pathway, Ravoxertinib aims to halt the proliferation and survival of cancer cells. Clinical trials have explored its efficacy as a monotherapy or in combination with other targeted therapies to enhance treatment outcomes. Its application is especially relevant in cases where resistance to other treatments, such as BRAF or MEK inhibitors, has developed. Ongoing research continues to evaluate its safety, dosage, and effectiveness in diverse cancer types.